MLYS
Mineralys Therapeutics, Inc.
22.10$
+0.6%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | -100.0% | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | +12.5% | +22.2% | +54.5% | -11.8% | +6.7% | -6.3% | -13.3% | -53.8% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | -188.2% | – | – | – | – | – | – | |
| – | +2.4% | -17.5% | +8.3% | +29.0% | +57.2% | -3.3% | +89.3% | +5.3% | +29.8% | +27.7% | +37.5% | -17.4% | -15.0% | +1.1% | -17.8% | -22.4% | -0.2% | +808.6% | – | |
| – | +69.4% | +11.8% | +54.3% | +60.6% | +20.8% | +45.6% | -2.0% | +6.7% | +14.5% | +27.9% | +3.8% | +17.6% | -8.8% | +28.9% | +14.3% | +43.4% | +51.1% | +17.6% | – | |
| – | +6.9% | -14.4% | +14.6% | +34.8% | +49.3% | +5.3% | +67.0% | +5.5% | +27.6% | +27.8% | +33.1% | -13.9% | -14.1% | +5.2% | -12.0% | -6.9% | +18.4% | +442.7% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | -210.7% | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | +25.5% | -1,448.4% | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.